We are live on ! Find out more
IGC icon

IGC Pharma
IGC

6 hedge funds and large institutions have $462K invested in IGC Pharma in 2014 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 2

20% more funds holding

Funds holding: 5 → 6 (+1)

0.96% less ownership

Funds ownership: 4.43% → 3.47% (-0.96%)

45% less capital inflows, than outflows

Capital inflows: $20K | Capital outflows: $36K

Holders
6
Holders Change
+1
Holders Change %
+20%
% of All Funds
0.17%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
2
Reduced
–
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Goldman Sachs
Goldman Sachs
New York
+$11.8K
2
Creative Planning
Creative Planning
Kansas
+$6.75K
3
Vantage Investment Advisors
Vantage Investment Advisors
Pennsylvania
+$1.13K
4
B. Riley Wealth Advisors
B. Riley Wealth Advisors
Florida
+$254
5
Tower Research Capital (TRC)
Tower Research Capital (TRC)
New York
+$31

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$34K
2
UBS
UBS
Switzerland
-$2K

IGC Hedge Fund Activity: Q2 2014 in Review

6 of the 3,491 institutional investors tracked by Wall St. Rank reported a position in IGC Pharma (IGC) for Q2 2014, worth a combined $462K — up 68% from $276K a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new IGC positions and 2 closed out — a net gain of 1 holder — while 2 added to existing stakes and 0 trimmed.

The largest buyer was Goldman Sachs, opening a new position worth an estimated $11.8K. The largest seller was Citadel Advisors, exiting entirely with an estimated $34K sold.

  • 6 institutional investors held IGC Pharma (IGC) as of Q2 2014, up from 5 in Q1 2014.
  • Funds reported $462K of IGC Pharma stock for Q2 2014, up 68% quarter-over-quarter.
  • 3 funds opened new IGC Pharma positions in Q2 2014 and 2 closed out, a net change of +1 holder.
  • The largest IGC Pharma buyer in Q2 2014 was Goldman Sachs, an estimated $11.8K added.
  • The largest IGC Pharma seller in Q2 2014 was Citadel Advisors, an estimated $34K sold.

Based on aggregated 13F filings for Q2 2014.